We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Whoopi Goldberg has warned fans about a fake advertisement, which features an AI-edited video of her endorsing a weight loss ...
Weight-loss jabs such as Ozempic are being hailed as a potential breakthrough in the fight against obesity. Demand, fuelled ...
The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Demand for weight loss injections has skyrocketed in just one year, with Google searches for the treatment rising by almost ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
More U.S. adults believe it is a good thing rather than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback